Deep learning-based prediction of HER2 status from breast diffusion-weighted MRI.
4 affiliations
- 1Department of Radiology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
- 2School of Physics and Optoelectronic Engineering, Yangtze University, Jingzhou, China.
- 3Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
- 4Department of Radiology, University of California, San Diego, San Diego, CA, United States.
Abstract
Background and objective
The accurate classification of human epidermal growth factor receptor 2 (HER2) status is very important for the diagnosis and treatment of breast cancer. However, the biopsy, the current gold standard for differentiating HER2 status, is invasive and time-consuming. To overcome these drawbacks, a novel deep learning model was developed to differentiate HER2-negative and HER2-positive status in breast cancer solely based on diffusion-weighted imaging (DWI).Materials and methods
This retrospective study included 239 women patients confirmed with breast cancer from two local medical centers. A hybrid CNN-Transformer DL model was proposed, which took DWI images (the ADC maps, DWI images with b = 0 s/mm² and b = 800 s/mm²) as inputs and output the classification of HER2-negative and HER2-positive status. Classification by the proposed DL model was quantitatively compared to the classification by the other benchmark DL models and two clinical experts.Results
Data of the 239 patients (mean age, 49.4 ± 10.0 years) were separated into a training set (n = 156), an internal test set (n = 39), and an external test set (n = 44). On the internal test set, the proposed DL model performed numerically better than the best benchmark DL model (area under the curve [AUC]: 0.93 vs. 0.89; accuracy: 0.90 vs. 0.85). On the external test set, the proposed model also performed numerically better than the best benchmark model (AUC: 0.91 vs. 0.87; accuracy: 0.84 vs. 0.82), and significantly better than the two clinical experts (AUC: 0.91 vs. 0.65 vs. 0.63; accuracy: 0.84 vs. 0.61 vs. 0.57).Conclusion
This study demonstrates the promise of combining DWI and DL for the classification of HER2 status in breast cancer, and it may potentially serve as a non-invasive adjunct or decision-support tool.
Related
- Multi-b-value diffusion-weighted imaging-based habitat imaging for preoperative prediction of histological grade and prognosis in soft tissue sarcoma: focusing on intratumoral heterogeneity
- Diffusion-Weighted MRI of Breast Lesions: A Five-Case Series Demonstrating Imaging Patterns and Diagnostic Pitfalls.
- Diffusion-Weighted Whole-Body Imaging with Background Body Signal Suppression (DWIBS)-Based Non-Contrast Breast MRI Screening: Initial Real-World Outcomes of a Non-Population-Based Program
- Evaluation of accelerated whole-body diffusion weighted imaging with deep learning reconstruction in patients with metastatic prostate cancer: assessment of image quality and ADC estimates.
- Deep learning reconstruction-applied PROPELLER diffusion-weighted imaging in uterine malignancies: a comparison study with MUSE
BibTeX
@article{zhang2026deep,
title = {{Deep learning-based prediction of HER2 status from breast diffusion-weighted MRI.}},
author = {Yao Zhang and Xinran Kan and Jiaqi Wang and Jie Peng and Jun Cai and Yajun Ma and Cheng Wang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1863720},
url = {https://europepmc.org/article/MED/42846412},
note = {CC BY},
}
RIS
TY - JOUR
TI - Deep learning-based prediction of HER2 status from breast diffusion-weighted MRI.
AU - Yao Zhang
AU - Xinran Kan
AU - Jiaqi Wang
AU - Jie Peng
AU - Jun Cai
AU - Yajun Ma
AU - Cheng Wang
PY - 2026
DA - 2026/10/05
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1863720
UR - https://europepmc.org/article/MED/42846412
AB - Background and objective The accurate classification of human epidermal growth factor receptor 2 (HER2) status is very important for the diagnosis and treatment of breast cancer. However, the biopsy, the current gold standard for differentiating HER2 status, is invasive and time-consuming. To overcome these drawbacks, a novel deep learning model was developed to differentiate HER2-negative and HER2-positive status in breast cancer solely based on diffusion-weighted imaging (DWI).Materials and methods This retrospective study included 239 women patients confirmed with breast cancer from two local medical centers. A hybrid CNN-Transformer DL model was proposed, which took DWI images (the ADC maps, DWI images with b = 0 s/mm² and b = 800 s/mm²) as inputs and output the classification of HER2-negative and HER2-positive status. Classification by the proposed DL model was quantitatively compared to the classification by the other benchmark DL models and two clinical experts.Results Data of the 239 patients (mean age, 49.4 ± 10.0 years) were separated into a training set (n = 156), an internal test set (n = 39), and an external test set (n = 44). On the internal test set, the proposed DL model performed numerically better than the best benchmark DL model (area under the curve [AUC]: 0.93 vs. 0.89; accuracy: 0.90 vs. 0.85). On the external test set, the proposed model also performed numerically better than the best benchmark model (AUC: 0.91 vs. 0.87; accuracy: 0.84 vs. 0.82), and significantly better than the two clinical experts (AUC: 0.91 vs. 0.65 vs. 0.63; accuracy: 0.84 vs. 0.61 vs. 0.57).Conclusion This study demonstrates the promise of combining DWI and DL for the classification of HER2 status in breast cancer, and it may potentially serve as a non-invasive adjunct or decision-support tool.
SN - 2234-943X
ER -